Ella (Ulipristal Acetate) Patent Expiration, LOE Window & CMS Spending

Ella (Ulipristal Acetate) by Laboratoire Hra: FDA Orange Book LOE 2030-06-12, 1 AB generics, $5.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLaboratoire Hra
FDA Application & PathwayN022474 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-06-12
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$5.2M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$5.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel